NCT06196775View on ClinicalTrials.gov

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

AK104+AK112

Cadonilimab (AK104): 10mg/kg or 15mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) AK112: 20mg/kg Q3W iv D1 Eligible patients will receive AK104 plus AK112 until disease progression or withdrawn ICF or death, whichever comes first.

Trial Locations (1)

Unknown

Harbin Medical University Hospital, Harbin

All Listed Sponsors
lead

Harbin Medical University

OTHER

NCT06196775 - A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter